Related references
Note: Only part of the references are listed.Outcomes after biochemical or clinical progression in patients with multiple myeloma
Sarah Goldman-Mazur et al.
BLOOD ADVANCES (2023)
How I treat high-risk multiple myeloma
Elena Zamagni et al.
BLOOD (2022)
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
Sriram Ravichandran et al.
LEUKEMIA (2022)
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine
Ankit K. Dutta et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2022)
A simple additive staging system for newly diagnosed multiple myeloma
Nadine H. Abdallah et al.
BLOOD CANCER JOURNAL (2022)
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH
Yuting Yan et al.
BLOOD ADVANCES (2022)
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo et al.
BLOOD (2022)
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
Ruth M. de Tute et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Mattia D'Agostino et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
Kristine Misund et al.
LEUKEMIA (2022)
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma
Ceri Bygrave et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
James Croft et al.
LEUKEMIA (2021)
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Karthik Ramasamy et al.
BLOOD REVIEWS (2021)
Current approaches to management of high-risk multiple myeloma
Sarah Goldman-Mazur et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Progression signature underlies clonal evolution and dissemination of multiple myeloma
Yu Jia Shen et al.
BLOOD (2021)
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond et al.
Lancet Haematology (2021)
CAR T-cell therapy for multiple myeloma: state of the art and prospects
Niels W C J van de Donk et al.
Lancet Haematology (2021)
Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy
Hisao Imai et al.
ONCOLOGY (2021)
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
Gang An et al.
LEUKEMIA (2020)
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma
Efstathios Kastritis et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
Jill Corre et al.
HAEMATOLOGICA (2020)
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients
Juan Du et al.
ANNALS OF HEMATOLOGY (2020)
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
Mattia D'Agostino et al.
CLINICAL CANCER RESEARCH (2020)
Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI
Chi-Lu Chiang et al.
TARGETED ONCOLOGY (2020)
Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review
Roman Hajek et al.
BMJ OPEN (2020)
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1
Selina J. Chavda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
John R. Jones et al.
HAEMATOLOGICA (2019)
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
Roman Hajek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Progression with clinical features is associated with worse subsequent survival in multiple myeloma
Rajshekhar Chakraborty et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience
Holly Lee et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Multiple myeloma clonal evolution in homogeneously treated patients
Jill Corre et al.
LEUKEMIA (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
Jian Hou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma
N. Tandon et al.
BLOOD CANCER JOURNAL (2017)
Clinical significance of post-progression survival in lung cancer
Hisao Imai et al.
THORACIC CANCER (2017)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET HAEMATOLOGY (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
Gordon Cook et al.
LANCET ONCOLOGY (2014)
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
B. Paiva et al.
LEUKEMIA (2013)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
Impact of early relapse after auto-SCT for multiple myeloma
S. Kumar et al.
BONE MARROW TRANSPLANTATION (2008)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
